FY2024 Earnings Estimate for Design Therapeutics, Inc. (NASDAQ:DSGN) Issued By Leerink Partnrs

Design Therapeutics, Inc. (NASDAQ:DSGN) – Equities researchers at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Design Therapeutics in a report issued on Monday, August 5th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.87) per share for the year, up from their prior forecast of ($0.89). The consensus estimate for Design Therapeutics’ current full-year earnings is ($1.02) per share. Leerink Partnrs also issued estimates for Design Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.96) EPS and FY2026 earnings at ($1.13) EPS.

DSGN has been the topic of a number of other research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research note on Tuesday. Piper Sandler raised Design Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $6.00 to $12.00 in a research note on Tuesday, May 7th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Design Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.60.

Design Therapeutics Trading Up 4.4 %

NASDAQ DSGN traded up $0.18 on Thursday, reaching $4.24. 921,323 shares of the company were exchanged, compared to its average volume of 242,688. The business’s fifty day moving average price is $4.00 and its 200 day moving average price is $3.57. The stock has a market capitalization of $239.54 million, a P/E ratio of -4.04 and a beta of 1.83. Design Therapeutics has a fifty-two week low of $1.94 and a fifty-two week high of $7.83.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Baker BROS. Advisors LP raised its position in Design Therapeutics by 10.8% in the first quarter. Baker BROS. Advisors LP now owns 1,662,120 shares of the company’s stock worth $6,698,000 after acquiring an additional 162,120 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Design Therapeutics by 29.0% in the first quarter. Vanguard Group Inc. now owns 1,285,962 shares of the company’s stock valued at $5,182,000 after buying an additional 288,803 shares in the last quarter. BML Capital Management LLC purchased a new position in shares of Design Therapeutics in the fourth quarter valued at $2,728,000. Acadian Asset Management LLC increased its position in shares of Design Therapeutics by 44.5% in the second quarter. Acadian Asset Management LLC now owns 583,160 shares of the company’s stock valued at $1,952,000 after buying an additional 179,614 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Design Therapeutics by 41.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 347,794 shares of the company’s stock worth $1,402,000 after purchasing an additional 102,567 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.